Skip to main content

Navigation principale

  • About
  • Team
  • Portfolio
  • Strategy
  • Testimonials
  • News
  • Contact

Secondary Navigation

  • Fr
  • En

News

You are here

  • Home
  • News
A-Mansia Biotech

Belgian world premiere! A new generation bacterium will be placed on the European market. Her name? Akkermansia muciniphila

Post date
29/06/2022

A major turning point for people at risk of cardiovascular disease, obesity and diabetes.

Mont-Saint-Guibert, June 29, 2022

  • A crucial step has been taken by the Belgian company The Akkermansia
Read more
Virovet

ViroVet completes series C funding: Animal health company raised close to 20 million Euro since its start in 2016

Post date
16/06/2022

LEUVEN, Belgium, June 16th, 2022 — ViroVet NV, a leading Belgian biopharmaceutical company active in the development of innovative vaccines and antiviral drugs for livestock, is proud to announce that

Read more
Syndesi Therapeutics

VIVES’ Portfolio Company Syndesi Therapeutics acquired by AbbVie

Post date
02/03/2022

Louvain-la-Neuve, March 1, 2022 – VIVES today announced that AbbVie (NYSE: ABBV) has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie’s neuroscience portfolio.

Read more
Sunrise

Sunrise secures €6.5 million in funding to deploy its sleep apnea diagnostic solution internationally

Post date
14/12/2021

Sunrise, a healthtech company founded in 2015 in Belgium, has just closed a €3.25 million fundraising round. Led by Kurma Partners, this round of financing, in which the Vives-IUF fund linked to

Read more
Novadip

Novadip Biosciences announces EUR 19 million Series B financing backed by international investors

Post date
28/10/2021

Mont Saint-Guibert, Belgium – October 28, 2021 – Novadip Biosciences, a clinical stage company developing treatments to regenerate impaired tissue in patients with significant unmet medical needs,

Read more
VOCSens

The Walloon start-up “VOCSens” raises €2.5 million to deploy its new concept of environmental camera

Post date
22/10/2021

Louvain-la-Neuve, 22 October 2021 – VOCSens raises €2.5 million in seed funding in order to industrialise its gas microsensors. The objective? The aim is to commercialise its micro gas sensors in the

Read more
Virovet

ViroVet and The Pirbright Institute are first to demonstrate efficacy of antivirals in ASFV infected pigs

Post date
09/09/2021

Belgian biotechnology company ViroVet partnered with researchers at The Pirbright Institute in 2019 to develop and test the first antiviral drugs that act against African swine fever (ASF). In the

Read more
A-Mansia

European green light for the bacterium of A-Mansia Biotech

Post date
01/09/2021

European first in next-generation bacterium: pasteurized Akkermansia muciniphila from A-Mansia Biotech receives the green light from EFSA's scientific committee.

Excellent news for people at risk of

Read more
Promethera

Walloon company Promethera announces a € 20 millions financing round

Post date
30/06/2021

This new fundraising secures the financing of its Phase IIB study for HepaStem® in its flagship indication, Acute on Chronic Liver Failure (ACLF), a severe liver disease affecting more than 50000

Read more
LMO

LMO secures funding from VIVES Inter-University Fund of UCLouvain

Post date
29/06/2021

LUXEMBOURG, June 29, 2021 – LMO, a company developing precision maneuvering technologies for in-space operations, with offices in Luxembourg and UK, secures funding from VIVES Inter-University Fund,

Read more
Novadip

Novadip Biosciences reports positive data from phase I study of NVD-001 for spinal fusion.

Post date
15/06/2021

Mont-Saint-Guibert, June 15, 2021 – Novadip Biosciences (“Novadip”), a clinical stage company developing treatments to regenerate impaired tissues in patients with significant unmet medical needs,

Read more
Tessares

Tessares welcomes new strategic investors and concludes a new round of funding as it prepares to launch a Wi-Fi/cellular convergence solution

Post date
31/03/2021

March 31, 2021 - Louvain-la-Neuve, Belgium: Tessares - a technology company specializing in Hybrid Access software - has just concluded a new round of funding to fast forward an innovative software

Read more

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Next page ››
  • Last page Last »
 

VIVES Funds

VIVES Funds
Bâtiment Le Parc
Place de l’Université 16 bte 27
1348 Louvain-la-Neuve
Belgium

Email
info@sopartec.com
Téléphone
+32 (0)10.39.00.21
Fax
+32 (0)10.39.00.29
Fichier Plan d'accès

Contact

Maximum 5 files.
64 MB limit.
Allowed types: txt rtf pdf doc docx odt ppt pptx odp xls xlsx ods.
Read the general policy of protection of personal data.

VIVES is a multi-sector technology fund that invests in spin-offs from UCLouvain and start-ups in Belgium and neighboring countries. The fund has the ability to invest at different stages of a company's development: seed, start-up and growth.

Menu Pied de page

  • Privacy policy & cookies
  • Terms & conditions
  • © 2022 VIVES fund All rights reserved.
  • Website by Visible